ACLX - NASDAQ
Arcellx, Inc.
$115.07
+0.0000%Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
At a Glance
Live SnapshotArcellx, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Arcellx, Inc. Cash Flow Statement
ACLX • NASDAQ
| Arcellx, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-228.9M | -107.3M | -70.7M | -188.7M | -65M | -32.1M | -18M | -8.3M | |
-1.8M | 5.2M | 2M | 1.3M | 1M | 629K | 326K | 93K | |
77.9M | 61.1M | 41.8M | 21.5M | 6.8M | 1.1M | 136K | 66K | |
44K | -11.6M | 9M | 62.1M | 213K | 0.0 | 0.0 | 856K | |
(0.0) | (1.6M) | (212K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-57.5M | -30.8M | 225.4M | 4.5M | 2.7M | 1.8M | -1.3M | 432K | |
-210.3M | -83.5M | 207.6M | -99.3M | -54.2M | -28.7M | -18.8M | -6.9M | |
INVESTING ACTIVITIES | ||||||||
-2.3M | -13.4M | -21.4M | -2.3M | -5.8M | -888K | -3.8M | -479K | |
(0.0) | (0.0) | (0.0) | (115.4M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-407M | -597.3M | -442.4M | -273.7M | -74.2M | (0.0) | (0.0) | (0.0) | |
495.6M | 427.7M | 309.3M | 158.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -115.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
(86.3M) | -183M | -154.5M | -117.7M | -80M | -888K | -3.8M | -479K | |
FINANCING ACTIVITIES | ||||||||
137.2M | 15.8M | 299.7M | 259.8M | -24K | 0.0 | 0.0 | 0.0 | |
-230K | -39.8M | -29.4M | -9.7M | -387K | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | -24K | (0.0) | (0.0) | (0.0) | |
-38.4M | 0.0 | 8.8M | 2.5M | -256K | -1.1M | 86K | 12.5M | |
98.5M | -24.1M | 279.2M | 252.6M | 118.5M | 41.7M | 42.7M | 12.5M | |
CASH FLOW SUMMARY | ||||||||
-25.4M | -290.6M | 332.2M | 35.6M | -15.8M | 12.1M | 20M | 5.1M | |
108.3M | 398.9M | 66.7M | 31M | 46.8M | 34.7M | 14.6M | 9.5M | |
82.9M | 108.3M | 398.9M | 66.7M | 31M | 46.8M | 34.7M | 14.6M | |
-212.6M | -96.9M | 186.1M | -101.6M | -60M | -29.6M | -22.6M | -7.3M |
SEC Filings
ACLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 24, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 22, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 28, 2025 | May 28, 2025 | 2025 |
Related Guides
Continue your ACLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.